Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Tupulak who wrote (78)	10/23/1999 10:05:00 AM
From: Tupulak	Read Replies (1) \| Respond to of 164

NEWS RELEASE OCT. 22/99 SYNSORB Biotech Inc. Announces Correction CALGARY, ALBERTA--SYNSORB Biotech Inc. ("SYNSORB") (TSE:SYB, NASDAQ: SYBB) announced today that contrary to a report appearing in the National Post and Calgary Herald newspapers, its subsidiary, Oncolytics Biotech Inc. ("Oncolytics") has not been approved by Health Canada to begin human testing of the reovirus. Oncolytics is preparing an Investigational New Drug Submission to begin a Phase I human trial in Canada concerning the use of the reovirus as a potential cancer therapeutic. This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. These factors include results of current or pending clinical trials, actions by the FDA/HPB and those factors detailed in the Company's registration statement on Form 20 F filed with the Securities and Exchange Commission. The common shares have not been and will not be registered under the United States Securities Act of 1993, as amended (the "1933 Act"), and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons except in certain transactions exempt from the registration requirements of the 1933 Act. -30- FOR FURTHER INFORMATION PLEASE CONTACT: SYNSORB Biotech Inc. David Cox, Ph.D. President & CEO (403) 283-5900 (403) 283-5907 (FAX) synsorb.com